(+)-Calanolide A

Drug Profile

(+)-Calanolide A

Alternative Names: Calanolide A; NSC 664737; NSC 675451

Latest Information Update: 27 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer Sarawak MediChem Pharmaceuticals
  • Class Antiretrovirals
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported HIV-1 infections; Tuberculosis

Most Recent Events

  • 13 Jun 2006 Phase-I clinical trials in Tuberculosis in USA (PO)
  • 04 Jun 2004 Preclinical trials in Tuberculosis in USA (PO)
  • 06 Mar 2003 Clinical data from a media release have been added to the adverse events and pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top